Shao Y, Yang W, Nanayakkara G, Saaoud F, Ben Issa M, Xu K
Int J Drug Discov Pharm. 2025; 3(4).
PMID: 39926714
PMC: 11804271.
DOI: 10.53941/ijddp.2024.100022.
Schoenherr C, Pietzsch S, Barca C, Muller F, Bahr F, Kasten M
Front Mol Med. 2025; 4():1487526.
PMID: 39834851
PMC: 11743445.
DOI: 10.3389/fmmed.2024.1487526.
Horiguchi H, Kadomatsu T, Oike Y
Cancer Sci. 2024; 116(3):592-599.
PMID: 39686837
PMC: 11875762.
DOI: 10.1111/cas.16434.
Leven A, Wagner N, Nienaber S, Messiha D, Tasdogan A, Ugurel S
Basic Res Cardiol. 2024; 120(1):133-152.
PMID: 39658699
PMC: 11790718.
DOI: 10.1007/s00395-024-01092-8.
Gao H, Chen Z, Yao Y, He Y, Hu X
Front Oncol. 2024; 14:1453090.
PMID: 39634266
PMC: 11614734.
DOI: 10.3389/fonc.2024.1453090.
Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System.
Milutinovic S, Jancic P, Jokic V, Petrovic M, Dumic I, Rodriguez A
Pharmaceuticals (Basel). 2024; 17(10).
PMID: 39459012
PMC: 11510316.
DOI: 10.3390/ph17101372.
Early identification of severe immune checkpoint inhibitor associated myocarditis: From an electrocardiographic perspective.
Gao Y, Zhang H, Qiu Y, Bian X, Wang X, Li Y
Cancer Med. 2024; 13(15):e7460.
PMID: 39082198
PMC: 11289619.
DOI: 10.1002/cam4.7460.
Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy.
Buehning F, Lerchner T, Vogel J, Hendgen-Cotta U, Totzeck M, Rassaf T
Basic Res Cardiol. 2024; 120(1):171-185.
PMID: 39039301
PMC: 11790694.
DOI: 10.1007/s00395-024-01070-0.
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart.
Munir A, Gutierrez A, Qin J, Lichtman A, Moslehi J
Nat Rev Cancer. 2024; 24(8):540-553.
PMID: 38982146
DOI: 10.1038/s41568-024-00715-5.
Anti-CTLA-4 m2a Antibody Exacerbates Cardiac Injury in Experimental Autoimmune Myocarditis Mice By Promoting Ccl5-Neutrophil Infiltration.
Wu M, Yang Y, Cai Y, Jiang S, Xiao H, Miao C
Adv Sci (Weinh). 2024; 11(34):e2400486.
PMID: 38978328
PMC: 11425905.
DOI: 10.1002/advs.202400486.
Cardiovascular disease burden in patients with urological cancers: The new discipline of uro-cardio-oncology.
Zheng Y, Liu Y, Chen Z, Zhang Y, Qi Z, Wu N
Cancer Innov. 2024; 3(2):e108.
PMID: 38946935
PMC: 11212304.
DOI: 10.1002/cai2.108.
Curcumin Nanoparticles-related Non-invasive Tumor Therapy, and Cardiotoxicity Relieve.
Cheng Y, Xu Q, Yu M, Dang C, Deng L, Chen H
Curr Med Chem. 2024; 32(3):447-467.
PMID: 38918994
PMC: 11826934.
DOI: 10.2174/0109298673305616240610153554.
Elevated IL-6 and Tumor Necrosis Factor-α in Immune Checkpoint Inhibitor Myocarditis.
Ali A, Caldwell R, Pina G, Beinart N, Jensen G, Yusuf S
Diseases. 2024; 12(5).
PMID: 38785743
PMC: 11120148.
DOI: 10.3390/diseases12050088.
Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination.
Watson R, Ye W, Taylor C, Jungkurth E, Cooper R, Tong O
J Immunother Cancer. 2024; 12(4).
PMID: 38663935
PMC: 11043765.
DOI: 10.1136/jitc-2023-008151.
Immune checkpoint inhibitor-associated cardiovascular toxicities: A review.
Liu G, Chen T, Zhang X, Hu B, Shi H
Heliyon. 2024; 10(5):e25747.
PMID: 38434280
PMC: 10907684.
DOI: 10.1016/j.heliyon.2024.e25747.
Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction.
Michel L, Ferdinandy P, Rassaf T
Curr Heart Fail Rep. 2024; 21(3):214-223.
PMID: 38430308
PMC: 11090976.
DOI: 10.1007/s11897-024-00652-2.
CXCR5TIM-3PD-1 stem-like cytotoxic CD8 T cells: elevated in chronic rhinosinusitis and associated with disease severity.
Liu Z, Zhao Z, Xie H, Lu N, Liu J, Jiao Q
Front Immunol. 2024; 15:1295309.
PMID: 38426098
PMC: 10902131.
DOI: 10.3389/fimmu.2024.1295309.
The Heart of the Matter: Immune Checkpoint Inhibitors and Immune-Related Adverse Events on the Cardiovascular System.
Green C, Chacon J, Godinich B, Hock R, Kiesewetter M, Raynor M
Cancers (Basel). 2023; 15(24).
PMID: 38136253
PMC: 10742007.
DOI: 10.3390/cancers15245707.
Previous cardiovascular injury is a prerequisite for immune checkpoint inhibitor-associated lethal myocarditis in mice.
Rubio-Infante N, Castillo E, Alves-Figueiredo H, Ramos-Gonzalez M, Salazar-Ramirez F, Salas-Trevino D
ESC Heart Fail. 2023; 11(2):1249-1257.
PMID: 38049390
PMC: 10966245.
DOI: 10.1002/ehf2.14614.
Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects.
Paluri R, Pulipati Y, Regalla D
Oncol Rev. 2023; 17:11456.
PMID: 38045806
PMC: 10691592.
DOI: 10.3389/or.2023.11456.